News

Because the past few months in the stock market have been a wild emotional roller coaster, most investors are now looking for the most logical and fundamental reasons to justify investing in any

Investors who own Pfizer Inc. (NYSE: PFE) may have expected 2023 to be what football teams call a "rebuilding year." The company shifted its focus away from COVID-19 drugs and toward potential

Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward

Christmas came early for Cerevel Therapeutics shareholders courtesy of AbbVie Inc. (NYSE:ABBV). 

Last week, AbbVie announced a plan to acquire the Massachusetts-based biotechnology company in an

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant

Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused

Johnson & Johnson (NYSE: JNJ),  Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their

Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors

Marketbeat's stock screening tools are a wealth of investment ideas, including the 52-week low list. Stocks trading at 52-week lows often provide oversold value ready to spring back, given the

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results. Many

Because earnings guidance is a company's best effort to forecast its earnings, it is a leading cause of share price movement. However, simply raising or lowering guidance is not enough to move a

Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company’s results but has done

Abbott Laboratories (NYSE: ABT) share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

While the direction of the stock markets is unpredictable, the growth of the aging population is entirely predictable. Along with an aging population come additional healthcare, beauty and

If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart. 

The stock gapped up nearly 28% on July 17, after

The healthcare industry presents a fertile shopping ground for undervalued dividend stocks. S&P 500 components Pfizer Inc. (NYSE: PFE), Medtronic plc (NYSE: MDT) and Gilead Sciences Inc. (NASDAQ:

The market's fear indicator, the VIX index, is bobbing along at long-term lows and gives little indication of a looming correction, but investors should assume one is brewing. The index is down at